CHTP Financial Facts
Net loss per basic and diluted share of common stock: -0.06Interest expense: 0
See Full Income Statement
Accrued contract research and manufacturing: 378.45K
Accounts payable: 898.03K
See Full Balance Sheet
Earnings History for Chelsea Therapeutics International (CHTP)
|
Expand Research on CHTP
| Next EPS Date | 8/6/13 *Est. | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | +29.2% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | +0.3% |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Estimize EPS/Revs | Gd. | % Since | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 5/1/13 | Q113 | -$0.06 | -$0.05 | -$0.01 | N/A | N/A | N/A / N/A | N/A | -0.5% | Details | |
3/7/13  |
Q412 | -$0.03 | -$0.08 | +$0.05 | N/A | N/A | N/A / N/A | N/A | +3.9% | Details | |
| 8/7/12 |
Q212 | -$0.12 | -$0.19 | +$0.07 | N/A | N/A | N/A / N/A | N/A | 0% | Details | |
| 3/6/12 |
 |
Q411 | -$0.20 | -$0.32 | +$0.12 | N/A | N/A | N/A / N/A | N/A | -46.4% | Details |
| 11/2/11 |
|
Q311 | -$0.18 | -$0.27 | +$0.09 | N/A | N/A | N/A / N/A | N/A | -57.9% | Details |
| 7/26/11 |
|
Q211 | -$0.21 | -$0.25 | +$0.04 | N/A | N/A | N/A / N/A | N/A | -64.9% | Details |
| 5/9/11 |
|
Q111 | -$0.25 | -$0.23 | -$0.02 | N/A | N/A | N/A / N/A | N/A | -57.6% | Details |
| 3/2/11 |
|
Q410 | -$0.25 | -$0.23 | -$0.02 | N/A | N/A | N/A / N/A | N/A | -53.5% | Details |
